New date for presentation of report for third quarter 2012

Presentation of results for third quarter 2012 will take place on Wednesday 24 October 2012 at 09:00 (Norwegian time), and not on Tuesday 30 October 2012 as per earlier announcement. The venue for the presentation is Felix Conference Centre, Bryggetorget 3, Aker brygge in Oslo.

The presentation will be available on webcast with the following link:

http://presenter.qbrick.com/?pguid=2e8ecac5-6551-4e31-89b9-a9df4f44bfd3  

After the presentation the webcast will be available on demand on the webpage www.diagenic.com under ‘Investor relations’.

Contact:

Paul de Potocki, Chief Executive Officer and President

Telephone: 47 4047 3060

e-mail: paul.depotocki@diagenic.com

About DiaGenic ASA

DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.

DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).

DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com